Trinity Biotech (TRIB) has secured regulatory clearances in multiple countries, enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer which is now available in more than 10 countries, including the United States. The upgraded system significantly increases testing throughput, improves operational efficiency, and supports greater recurring revenue opportunities and margin expansion as the company strengthens its leadership position in the growing global HbA1c market. Designed for Trinity Biotech’s Premier Hb9210 analyzer, the company’s dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimizes instrument downtime through improved stability and reduced maintenance requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test
- Trinity Biotech Collaborates to Enhance Prostate Cancer Test
- Trinity Biotech secures regulatory approval for outsourced manufacturing
- Trinity Biotech collabs to advance analysis on data for EpiCapture
- Trinity notes Perceptive Advisors’ indication of debt-to-equity conversion